British drug maker, AstraZeneca, announced their late-stage clinical trial data shows their new antibody treatment, AZD7442, reduces the risk of developing COVID-19 symptoms by 77%. The study gives hope to sufferers whose immune system did not generate a strong protective response after inoculation. The clinical trial tested the response of AstraZeneca’s AZD7442 therapy in people with chronic conditions and with lower immune responses to COVID-19 vaccinations. The AstraZeneca AZD7442 therapy is characterized by lab-made antibodies that are made to stay longer in the body to fight against the coronavirus. AstraZeneca is the first to present positive prevention trial data and is now planning prepare for approval in targeted markets and to deliver approximately 1-2 million doses by the end of 2021.
Read more here.